LYTIX — Lytix Biopharma AS Cashflow Statement
0.000.00%
Last trade - 00:00- NOK675.80m
- NOK605.64m
Annual cashflow statement for Lytix Biopharma AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
C2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | NAS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -48.1 | -56.1 | -87.9 | -94.3 | -60 |
| Depreciation | |||||
| Non-Cash Items | 4.05 | 1.38 | 4.18 | 0.878 | 13.8 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.04 | 1.15 | -13.2 | 22.1 | -14.7 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -44.6 | -52.6 | -96 | -70.4 | -59.9 |
| Capital Expenditures | 0 | -0.154 | -0.049 | 0 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.138 | -49.2 | 29.8 | 24.7 | -59.4 |
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.138 | -49.4 | 29.7 | 24.7 | -59.4 |
| Financing Cash Flow Items | -11.5 | -0.055 | -0.003 | -11.3 | -0.008 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 213 | -0.749 | -0.943 | 149 | -0.908 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 169 | -103 | -67.2 | 103 | -120 |